Clinical Study of DMT Inhalant for Treatment-Resistant Depression Completes Dosing Stage
Biomind Labs Inc. BMNDF, a life science company developing next-generation medicinal psychedelics, has completed dosing 30 healthy subjects in its clinical trial Phase 2 trial of proprietary DMT-based drug BMND01 for Treatment Resistant Depression Disorder (TDR).
In addition to producing new drugs based on first generation psychedelics such as DMT, 5-MeO-DMT and mescaline, Biomind seeks to create innovative nanotechnology delivery systems to treat psychiatric and neurological disorders.
The clinical study aims to establish the safety and tolerability of Biomind's proprietary DMT formulation, while evaluating side effects and how they might arise from a number physiological, behavioral and cognitive markers that will be collected before, during and after the test.
"The results of this first part of the world's first clinical trial to test an inhaled formulation of DMT are expected to be ready in October 2022," said CEO Alejandro Antalich.
According to Antalich, the concentration-response trial design involves a fixed two-dose ascending dose that allows DMT to enter the systemic circulation directly in approximately 10 minutes. This method bypasses first-pass metabolism, a major problem for some routes of DMT administration.
Furthermore, reducing the length of experience would provide "greater practical applicability for potentially delivering the psychedelic treatment in a supervised, real-life clinical setting," as the CEO explained. from Biomind.
Photo courtesy of Anna Shvets at Pexels and Jynto at Wikimedia Commons.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
CANNABIS BENZINGA CONFERENCEMeet the biggest players in the cannabis industry and strike deals that will drive the industry forward.
Featuring live company presentations, insider panels and unparalleled access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet .
Join us September 13-14, 2022 at The Palmer House in Chicago, IL.
Biomind Labs Inc. BMNDF, a life science company developing next-generation medicinal psychedelics, has completed dosing 30 healthy subjects in its clinical trial Phase 2 trial of proprietary DMT-based drug BMND01 for Treatment Resistant Depression Disorder (TDR).
In addition to producing new drugs based on first generation psychedelics such as DMT, 5-MeO-DMT and mescaline, Biomind seeks to create innovative nanotechnology delivery systems to treat psychiatric and neurological disorders.
The clinical study aims to establish the safety and tolerability of Biomind's proprietary DMT formulation, while evaluating side effects and how they might arise from a number physiological, behavioral and cognitive markers that will be collected before, during and after the test.
"The results of this first part of the world's first clinical trial to test an inhaled formulation of DMT are expected to be ready in October 2022," said CEO Alejandro Antalich.
According to Antalich, the concentration-response trial design involves a fixed two-dose ascending dose that allows DMT to enter the systemic circulation directly in approximately 10 minutes. This method bypasses first-pass metabolism, a major problem for some routes of DMT administration.
Furthermore, reducing the length of experience would provide "greater practical applicability for potentially delivering the psychedelic treatment in a supervised, real-life clinical setting," as the CEO explained. from Biomind.
Photo courtesy of Anna Shvets at Pexels and Jynto at Wikimedia Commons.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
CANNABIS BENZINGA CONFERENCEMeet the biggest players in the cannabis industry and strike deals that will drive the industry forward.
Featuring live company presentations, insider panels and unparalleled access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet .
Join us September 13-14, 2022 at The Palmer House in Chicago, IL.
What's Your Reaction?
